Second Addition to Amendment to Licensing Agreement dated March 30, 2017 between Resdevco Ltd. and Wize Pharma Ltd
EX-10.16 9 fs42017ex10-16_ophthalixinc.htm SECOND ADDITION TO AMENDMENT TO LICENSING AGREEMENT DATED MARCH 30, 2017 BETWEEN RESDEVCO LTD. AND WIZE PHARMA LTD.
Exhibit 10.16
Second Addition to the Amendment to Licensing Agreement - Worldwide rights to the
Unit Dose Eye Product — dated November 22, 2015
| 1. | From the Amendment to Licensing Agreement — Worldwide rights to the Unit Dose Eye Product — signed on November 22, 2015, section 3 — Rest of the world, the first paragraph is cancelled: |
“Resdevco grants Wize Pharma an option to purchase all the territories which are not under a signed contract for the amount of 3 Million USD and 0.3 UDS royalties per box of 30 unit for the dry-eye / Conjunctivochalasis product or equivalent royalties for boxes of different quantities.”
| 2. | Resdevco Ltd. and Wize Pharma Ltd. will keep open an option of a future discussion of purchasing the “rest of world”, under terms that will be mutually agreed upon. |
| 3. | The agreement: Addition to the Amendment to Licensing Agreement — Worldwide rights to the Unit Dose Eye Product — dated November 22, 2015, (signed on January 5, 2017) is cancelled |
| 4. | The 2017 minimum deductible annual royalty for the USA license: $150,000 + VAT, which was due originally on January 31, 2017, will be directly deposited in Resdevco’s account no later than May 31, 2017 at the exchange rate of 3.75 NIS per dollar. |
| Resdevco Ltd. | Wize Pharma Ltd. | |
| Name: Shabtay Dikstein | Name: Or Eisenberg | |
| Position: CEO | Position: CEO | |
| Signature: /s/ Prof. S. Dikstein | Signature: /s/ Or Eisenberg | |
| Date: March 30, 2017 | Date: March 30, 2017 |
